<DOC>
	<DOCNO>NCT02211261</DOCNO>
	<brief_summary>A first human study determine safety , tolerability pharmacokinetics single multiple ascend dos PF-06293620 subject Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety , Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Men woman nonchildbearing potential Type 2 Diabetes Mellitus Subjects stable dos metformin &gt; /= 1500 mg daily ( SAD cohort ) &gt; /= 1000 mg daily ( MAD cohort ) x 30 day prior screen HbA1c 710 % ( SAD Cohorts ) 6.510 % ( MAD cohort ) inclusive screen Fasting Cpeptide &gt; 1.12 ng/mL ( SAD cohort ) &gt; /= 0.8 mg/mL ( MAD cohort ) screen History Type 1 diabetes mellitus Evidence diabetic complication significant endorgan damage History chronic pancreatitis high risk pancreatitis Poorly control hypertension History cardiovascular cerebrovascular event procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>first human</keyword>
	<keyword>single dose</keyword>
	<keyword>multiple dose</keyword>
	<keyword>escalation</keyword>
	<keyword>safety study</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>